Session 9 – Biotech Business Models and Financing Strategy
Date: 23 July (Thursday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Shaun Grady has global responsibility for Business Development Operations at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including licensing and partnering, M&A, externalisation and divestments.
Shaun was appointed to his current role in 2013. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010 - 13) and Vice President, Corporate Business Development (2006 - 10).
Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca Group PLC.
Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT) and later MedImmune and led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ – BMS Diabetes Alliance. More recently Shaun led the transaction team for AZ’s global ADC collaboration with Daichi Sankyo for DS 8201.
Shaun has led AZ’s recent Externalisation and divestment programme involving transactions with Aspen, Grunenthal, Cheplapharm, Recordati and Covis.
Shaun is a Fellow in Entrepreneurship at Cambridge University Judge Business School and is a member of the Board of Cambridge United Football Club, Cambridge Arts Theatre, Healx and Prostate Cancer Research Centre.
Based in Cambridge, Shaun enjoys rugby and soccer, and occasionally turns his hand to sports writing.
Speech title & Synopsis
Audience will be interested in why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas AstraZeneca is looking for. AstraZeneca has been actively investing in startup Joint-Ventures and Accelerators in EU and Asia. What are the outcomes so far and what can we expect from these strategies?